Related Experiment Videos
Current status of cancer drug development: failure or limited success?
1Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285.
Abstract:
Murine leukemia models have been a major part of cancer drug screening strategies over the past 30 years. While these models have reliably identified agents active against human leukemias and lymphomas, they have been considerably less effective in identifying new agents for the treatment of common human solid tumors. This review considers the shortcomings of past approaches to cancer drug development, and describes new screening strategies designed to identify carcinoma-selective drugs.
Insights
Murine leukemia models effectively screen leukemia drugs but fail for solid tumors. New strategies are needed to discover carcinoma-selective cancer therapies.
Area of Science:
- Oncology
- Pharmacology
- Drug Discovery
Background:
- Murine leukemia models have been extensively utilized in cancer drug screening for three decades.
- These models have shown success in identifying agents for leukemias and lymphomas.
- However, they have demonstrated limited efficacy in discovering new treatments for common human solid tumors.
Purpose of the Study:
- To review the limitations of traditional cancer drug development approaches.
- To introduce novel screening strategies for identifying carcinoma-selective drugs.
Main Methods:
- Literature review of past and current cancer drug screening methodologies.
- Analysis of the effectiveness of murine leukemia models for solid tumor drug discovery.
- Description of emerging screening strategies focused on carcinoma selectivity.
Main Results:
- Established murine leukemia models are inadequate for identifying effective treatments for solid tumors.
- Significant shortcomings exist in current cancer drug development pipelines.
- New approaches are required to address the specific needs of solid tumor treatment.
Conclusions:
- Rethinking drug screening models is crucial for advancing cancer therapy.
- Development of carcinoma-selective screening strategies is essential for future cancer drug discovery.
- Novel approaches promise to improve the identification of agents targeting human solid tumors.